ADAPT Her2+/HR+ Study

Project Description

The ADAPT Her2+/HR+ Study is a WSG sponsored study, which involves the dynamic testing of Her2+/HR+ breast cancer patients. Palleos delivers a full-service management including Data Management, Project Management, Regulatory Affairs, Monitoring, IT infrastructure, site management, and financial management in Germany. For scientific details see the Sponsor’s homepage.

  • 380 Patients, 51 Sites [LPI: Q4 2014]
  • Indication: Oncology
  • CRO | Acting as preferred provider for the WSG | Full-service